MarketInOut Stock Screener Log In | Sign Up
 

AbCellera Biologics Inc

IEX • Healthcare • Biotechnology • Quote as of 10/23/2026
AbCellera Biologics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeIEX
Market Capitalization3,684.42 mln
Float254 mln
Earnings Date11/09/2026

Piotroski F-Score

5 / 9
Neutral

Beneish M-Score

-3.84
Highly reliable

1-Year Forecast

16.82
Exceptional upside

Relative Strength

28 / 100
Underperforming

Debt / Equity

0.15
Very low leverage

Pre-Tax Margin

-297%
Severely loss-making

Business Description

Founded in 2012 and based in Vancouver, Canada, AbCellera Biologics works to find and build new antibody treatments for patients who currently have few good options. The company has two drugs moving through clinical trials: one non-hormonal treatment for hot flashes and night sweats, and another targeting certain immune system disorders like atopic dermatitis. AbCellera works alongside major partners including Eli Lilly, AbbVie, and Biogen to advance its research and bring new medicines to market.

Key Fundamentals

EPS-0.54
ROE-17.25
RPS0.22
ROIC-24.44
ROA-12.23
EBITDA, mln-164
EV / EBITDA-26.76
EV / EBIT-22.33
Revenue, mln66.17
EV / Revenue66.39

Quote Details

Last 11.82
Change 0.45 (3.96%)
Open 11.45
Volume 2,707,677
Turnover 32,004,742
Average Volume 4,697,595

Financial Ratios

Pre-Tax Profit Margin-297
Leverage Ratio1.46
Current Ratio12.77
Price / Book5.10
Price / Tangible Book5.62
Debt / Equity0.15
Price / Sales68.07

Financial Strength

Altman Z-Score6.99
Piotroski F-Score 5 / 9
Beneish M-Score-3.84
Price to Intrinsic Value7.81
1-Year Target Price16.82
Short Ratio7.04
Short % of Float12.78

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 0.17% 52 / 100   
1 Month -6.56% 30 / 100   
2 Months 104% 100 / 100   
6 Months 184% 100 / 100   
1 Year 116% 97 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Blog